Ten-year mortality is increased after hospitalization for atopic dermatitis compared with the general population, but reduced compared with psoriasis - 18/04/17
, Lone Skov, MD, PhD, DMSc a, Yuki M.F. Andersen, MD a, Lotus Mallbris, MD, PhD c, Gunnar H. Gislason, MD, PhD b, d, e, Jonathan I. Silverberg, MD, PhD, MPH f, g, Jashin J. Wu, MD h, Jacob P. Thyssen, MD, PhD, DMSc aAbstract |
Background |
Psoriasis and atopic dermatitis (AD) are chronic inflammatory skin disorders. Mortality is increased in psoriasis, yet no studies on mortality in AD are currently available.
Objective |
We investigated 10-year mortality after hospitalization for AD compared with psoriasis and the general population.
Methods |
Between 1996 and 2002 all Danes aged 18 years or older with a first-time hospitalization as a result of AD or psoriasis and AD-matched healthy control subjects were examined in nationwide registers. Multivariable (adjusted for age, sex, socioeconomic status, Charlson Comorbidity Index score, smoking, and medication) hazard ratios were estimated by Cox regression.
Results |
The study comprised 576 and 951 hospitalized patients with AD and psoriasis, respectively, with a maximum follow-up time of 10 years. During the study period, there were 65 and 286 deaths among patients with AD and psoriasis. Risk of death was decreased in patients with AD versus psoriasis (hazard ratio 0.75; 95% confidence interval 0.57-1.00), but higher than in general population control subjects (n = 5760) (hazard ratio 1.71; 95% confidence interval 1.20-2.44). Patients hospitalized with AD died on average 8.3 years younger than control subjects.
Limitations |
Lifestyle may have affected the risk.
Conclusions |
The 10-year mortality was significantly lower after hospitalization for AD compared with psoriasis, but increased when compared with the general population.
Le texte complet de cet article est disponible en PDF.Key words : atopic dermatitis, epidemiology, inflammation, mortality, psoriasis
Abbreviations used : AD, CCI, CI, HR
Plan
| Funding sources: Drs Andersen and Thyssen are supported by an unrestricted grant from the Lundbeck Foundation. Dr Gislason is supported by an unrestricted research scholarship from the Novo Nordisk Foundation. |
|
| Disclosure: Dr Egeberg has received research funding and/or consultancy honoraria from Pfizer and Eli Lilly. Dr Skov has received consultancy and/or speaker honoraria from AbbVie, Pfizer, Janssen-Cilag, Merck Sharp & Dohme, and Leo Pharma and is a member of the advisory boards of AbbVie, Pfizer, Janssen-Cilag, Merck Sharp & Dohme, Eli Lilly, Celgene, and Novartis. Dr Mallbris is currently employed by Eli Lilly. Dr Wu received research funding from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Coherus Biosciences, Dermira, Eli Lilly, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, Regeneron, Sandoz, and Sun Pharmaceutical Industries; he is a consultant for AbbVie, Amgen, Celgene, Dermira, Eli Lilly, Pfizer, Regeneron, and Sun Pharmaceutical Industries. Dr Silverberg has received research support from the Dermatology Foundation and the Agency for Healthcare Research and Quality. Dr Thyssen has received speaker honoraria from Galderma and MEDA. Drs Andersen and Gislason have no conflicts of interest to declare to declare. |
Vol 76 - N° 1
P. 98-105 - janvier 2017 Retour au numéro
Article précédent
- Ustekinumab treatment in severe atopic dermatitis: Down-regulation of T-helper 2/22 expression
- Doris Weiss, Michaela Schaschinger, Robin Ristl, Robert Gruber, Tamara Kopp, Georg Stingl, Christine Bangert
- Cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis: Retrospective analysis of a cohort treated in a specialized referral center
- Haur Yueh Lee, Stephanie Fook-Chong, Hong Yi Koh, Tharmotharampillai Thirumoorthy, Shiu Ming Pang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?